Marta Coscia
A5035820057- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Advanced Breast Cancer Therapies
- Immune Cell Function and Interaction
- Acute Lymphoblastic Leukemia research
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Cancer-related Molecular Pathways
- Monoclonal and Polyclonal Antibodies Research
- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Gastrointestinal Tumor Research and Treatment
- Phagocytosis and Immune Regulation
- Cancer, Hypoxia, and Metabolism
- Calcium signaling and nucleotide metabolism
- Galectins and Cancer Biology
- Bone health and treatments
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Adenosine and Purinergic Signaling
- PI3K/AKT/mTOR signaling in cancer
- Glycosylation and Glycoproteins Research
- Acute Myeloid Leukemia Research
University of Turin
2016-2025
University of Insubria
2024-2025
Aziende Socio Sanitarie Territoriale dei Sette Laghi
2024-2025
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
2015-2024
Ospedale di Circolo e Fondazione Macchi
2024
Fred Hutch Cancer Center
2023
University of Washington
2023
University of Medical Sciences and Technology
2023
National Research Council
2023
Neuroscience Institute
2023
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study characterize course COVID-19 in and identify potential predictors outcome. Of 190 confirmed diagnosed between 28/03/2020 22/05/2020, 151 (79%) presented (need oxygen and/or intensive care admission). Severe was associated advanced...
Chronic lymphocytic leukemia is marked by profound defects in T-cell function. Programmed death-1 a receptor involved tumor-mediated immunosuppression through binding of the PD-L1 ligand. Multiparametric flow cytometry and immunohistochemistry were used to study PD-1/PD-L1 expression. Functional assays determine involvement axis responses. PD-1 expression CD4+ CD8+ T lymphocytes was significantly higher 117 chronic patients than 33 donors comparable age. from displayed increased numbers...
Abstract Patients with chronic lymphocytic leukemia (CLL) progressing on ibrutinib constitute an unmet need. Though Bruton tyrosine kinase (BTK) and PLCG2 mutations are associated resistance, their frequency relevance to progression not fully understood. In this multicenter retrospective observational study, we analyzed 98 patients CLL (49 relapsing after initial response 49 still responding ≥1 year of continuous treatment) using a next-generation sequencing (NGS) panel (1% sensitivity)...
It is unknown whether zoledronic acid (ZA) at clinically relevant doses active against tumours not located in bone. Mice transgenic for the activated ErbB-2 oncogene were treated with a cumulative number of equivalent to that recommended human beings. A significant increase tumour-free and overall survival was observed mice ZA. At compatible concentrations, ZA modulated mevalonate pathway affected protein prenylation both tumour cells macrophages. marked reduction tumour-associated...
is a recurrently mutated gene in chronic lymphocytic leukemia (CLL) but the functional implications of
Abstract Vγ9Vδ2 T cells play a major role as effector of innate immune responses against microbes, stressed cells, and tumor cells. They constitute <5% PBLs but can be expanded by zoledronic acid (ZA)-treated monocytes or dendritic (DC). Much less is known about their ability to act cellular adjuvants bridging adaptive immunity, especially in patients with cancer. We have addressed this issue multiple myeloma (MM), prototypic disease several dysfunctions that also affect γδ DC....
Vγ9Vδ2 T cells have a natural inclination to recognize malignant B in vitro via receptors for stress-induced self-ligands and TCR-dependent recognition of phosphoantigens (pAgs) generated the mevalonate (Mev) pathway. This is continuously challenged vivo by immune suppression operated tumor cells. Multiple myeloma (MM) prototypic B-cell malignancy which subvert local microenvironment reshape antitumor responses. In this study, we investigated competence bone marrow (BM) large series MM...
Chronic lymphocytic leukemia (CLL) is a variable disease; therefore, markers to identify aggressive forms are essential for patient management. Here, we have shown that expression of the costimulatory molecule and microbial sensor SLAMF1 (also known as CD150) lost in subset patients with an CLL associates shorter time first treatment reduced overall survival. silencing CLL-like Mec-1 cells, which constitutively express SLAMF1, modulated pathways related cell migration, cytoskeletal...
Key Points Hypoxia shapes the CLL lymph node microenvironment by acting through A2A adenosine receptor. Inhibiting receptor counteracts effects of hypoxia on cells, macrophages, and T lymphocytes.
In chronic lymphocytic leukemia (CLL), the hypoxia-inducible factor 1 (HIF-1) regulates response of tumor cells to hypoxia and their protective interactions with leukemic microenvironment. this study, we demonstrate that CLL from TP53-disrupted (TP53dis) patients have constitutively higher expression levels α-subunit HIF-1 (HIF-1α) increased transcriptional activity compared wild-type counterpart. TP53dis subset, HIF-1α upregulation is due reduced ubiquitin ligase von Hippel-Lindau protein...